Vaxart, Inc. (VXRT) has outlined its timeline for releasing top-line data from its Phase IIb COVID-19 clinical trial, targeting the first half of 2027. This significant development, which is backed by funding from the Biomedical Advanced Research and Development Authority (BARDA), was a key insight from the company’s Q2 2026 management view.
Steven Lo, President, CEO & Director of Vaxart, characterized the recent operational period, stating, ‘The second quarter and recent weeks marked a pivotal period of execution and progress for Vaxart.’ This sentiment aligns with the company’s achievement of a crucial milestone in July, which involved detailing the forthcoming data release schedule for its oral COVID-19 vaccine candidate.
The projected availability of Phase IIb top-line data in H1 2027 provides a clear forward-looking indicator for investors monitoring Vaxart’s clinical pipeline. The explicit mention of BARDA funding underscores the strategic governmental support for this program, potentially mitigating development risks and affirming the perceived importance of Vaxart’s approach to COVID-19 vaccination.
As Vaxart advances its clinical program towards this 2027 data readout, the Q2 2026 insights reinforce the company’s focused trajectory. The partnership with BARDA remains a critical component in the continued development and potential commercialization pathway for its innovative vaccine platform.
